Alpha Tau Medical

4:15 PM - 4:30 PM, Tuesday, June 4, 2019 ・ Theater 1
MedTech company Alpha Tau Medical focuses on R&D and commercialization of its breakthrough cancer treatment, Alpha DaRT, originally invented in 2003 by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) delivers high-precision alpha radiation, that is released when radioactive substances decay inside the tumor. The short-range alpha particles effectively kill the cancer cells while sparing the surrounding healthy tissue. Early clinical results showed that Alpha DaRT is safe and effective for treating squamous cell carcinoma tumors, with a 100% partial and 70% complete response rate. The company recently received the Sealed Source and Device (SSD) approval and the FDA’s IDE Approval and is collaborating with key cancer physicians and researchers worldwide to investigate the Alpha DaRT as a treatment for various solid tumor indications, including: - Pancreas - Liver - Head and Neck - GYN.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Israel
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CTO
Alpha Tau Medical